Physician profile
Laura Whiteley
NPI 1578557211
$5,739.54
in general payments reported to CMS, 2019-2025
35 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $867 · 2021: $617 · 2022: $643 · 2023: $926 · 2024: $802 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,637.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $712.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $455.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $392.33 | 2019-2020 | |
| Astellas Pharma US INC | $273.07 | 2020-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $218.74 | 2019-2025 | Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $206.24 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $193.22 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Medtronic, INC. | $153.33 | 2023 | Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.34 | 2019-2022 | |
| Pfizer INC. | $130.65 | 2020-2022 | |
| Dynavax Technologies Corporation | $129.20 | 2020-2025 | Heplisav-B |
| Sanofi Pasteur INC. | $114.88 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $113.63 | 2024-2025 | Gemtesa |
| Cranial Technologies, INC | $100.23 | 2019-2025 | Doc Band |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $85.79 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $85.22 | 2019-2021 | |
| Amgen INC. | $71.92 | 2019-2025 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $63.95 | 2022-2025 | |
| Irhythm Technologies, INC. | $53.56 | 2024 | Zio Xt Patch, Zio Monitor |
| Genentech USA, INC. | $43.51 | 2019-2021 | |
| Boston Scientific Corporation | $36.82 | 2024 | Watchman Flx |
| Inspire Medical Systems, INC. | $36.75 | 2024-2025 | Inspire |
| Abbvie INC. | $34.24 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $31.23 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $30.47 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $30.02 | 2020 | |
| Allergan, INC. | $27.77 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.23 | 2019 | |
| Hologic Sales and Service, LLC | $23.58 | 2025 | Thinprep 2000 Processor, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $19.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.28 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.53 | 2022 | |
| Gilead Sciences, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Whiteley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.